Clindamycin foam - Stiefel Laboratories

Drug Profile

Clindamycin foam - Stiefel Laboratories

Alternative Names: 1% Clindamycin phosphate foam; 1% Evoclin foam; Evoclin

Latest Information Update: 26 Apr 2011

Price : $50

At a glance

  • Originator Stiefel Laboratories
  • Class Antibacterials; Lincosamides; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Acne vulgaris
  • No development reported Folliculitis

Most Recent Events

  • 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
  • 28 Dec 2006 Connetics Corporation has been acquired and merged into Stiefel Laboratories
  • 14 Apr 2005 Connetics and Ventiv Health have entered into an agreement to co-promote Evoclin™ in USA for acne vulgaris
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top